Outset Medical Taps Veteran Leader to Drive Dialysis Tech Growth

SAN JOSE, CA – April 06, 2026 – Outset Medical, Inc. (Nasdaq: OM) today announced a significant reinforcement of its executive team, appointing industry veteran Derick Elliott as its new Executive Vice President of Commercial. The move, effective immediately, signals a strategic push to accelerate the adoption of its innovative Tablo Hemodialysis System across the U.S. healthcare landscape.

Elliott, who brings over three decades of sales and marketing leadership from MedTech giants like Stryker and Cardinal Health, will now helm Outset’s commercial operations. Reporting directly to Chair and CEO Leslie Trigg, he is tasked with expanding the company's footprint in acute, post-acute, and home healthcare settings. The appointment comes at a pivotal moment for Outset, as it aims to build on recent financial gains and solidify its position as a disruptor in the multi-billion-dollar kidney care market.

A Strategic Play to Accelerate Commercial Growth

Derick Elliott’s appointment is widely seen as a targeted move to address one of the company's key challenges: capital sales predictability. While Outset Medical reported a 5% increase in full-year revenue for 2025, reaching $119.5 million, and significant gross margin expansion, the company also experienced a wider-than-expected earnings loss in its fourth quarter. The leadership team has previously acknowledged the need to smooth out its capital sales cycle, and Elliott's background appears tailor-made for the task.

Most recently, Elliott served as Chief Commercial Officer at SpendMend, where he successfully implemented a commercial strategy that mirrors Outset’s own model: leveraging a platform combining software, technology, and services to drive practice changes and deliver tangible financial and operational benefits to healthcare providers.

“Derick joins Outset at an ideal time as we expand our differentiated offering with new technology and services, and build on an already established base of clinical, operational and financial evidence,” said Ms. Trigg in the company's official announcement. She emphasized his “strong track record of commercial strategy and execution across capital equipment, software, EMR connectivity and other recurring revenue streams.”

This experience is critical as Outset transitions to an enterprise-based sales model and expands its EMR integration capabilities, both aimed at boosting its stable of recurring revenue, which grew 6% to $88.7 million in 2025. With 2026 revenue guidance projecting a 5% to 9% increase, Elliott's leadership will be instrumental in meeting those targets and building investor confidence.

Riding the Wave of Dialysis Insourcing

At the core of Outset’s strategy is the growing trend of dialysis insourcing. Historically, many hospitals have outsourced their dialysis services to third-party providers. However, a growing number are now bringing these services in-house to gain greater control over costs, staffing, and patient care quality.

The Tablo Hemodialysis System is purpose-built to facilitate this shift. Unlike traditional, complex dialysis setups that require separate water purification systems and pre-mixed dialysate, Tablo is an all-in-one, integrated unit. It purifies water and produces dialysate on demand, connecting directly to a standard tap water source and electrical outlet. This design drastically reduces the cost and complexity that have long been barriers to insourcing.

By empowering hospitals to manage their own dialysis programs, Outset enables them to capture significant cost savings, improve operational efficiency, and potentially enhance patient outcomes by providing more timely care. The company’s leadership often states that its primary competitor is not another device manufacturer, but rather the “status quo” of outsourced care. Elliott’s role will be to convince more of the nearly 1,000 U.S. healthcare facilities already using Tablo, and countless others, to fully embrace this new model.

The Veteran Leader for a New Era of Kidney Care

Elliott’s extensive resume makes him a formidable asset in the competitive MedTech talent landscape. His 17-year tenure at Stryker, culminating in his role as Vice President of Customer Solutions, and over a decade at Cardinal Health have endowed him with deep industry knowledge and, as Trigg noted, “broad and deep relationships with leading U.S. healthcare providers.”

This network will be invaluable as Outset continues its expansion. The company has already achieved significant scale, with its Tablo systems having delivered millions of treatments. The challenge now is to deepen its penetration within existing health systems and win over new ones.

For his part, Elliott expressed enthusiasm for the company’s mission and market position. “I have been impressed with the Outset management team, board and marquee roster of customers using Tablo to insource dialysis,” he stated. “This is a motivated team with a highly differentiated solution in one of the largest corners of healthcare. I am excited by the opportunity to help the company deliver the benefits of insourcing to an even broader set of customers.”

Navigating a Competitive Market and Future Innovations

While Outset focuses on disrupting the status quo, it operates in a market with entrenched giants like Fresenius Medical Care and DaVita. The company’s key differentiator remains its technology. The Tablo system’s FDA clearance for use from the hospital to the home gives it a unique advantage, allowing health systems to create a seamless continuum of care for kidney patients.

Elliott's arrival is also timed with further innovation. In January 2026, Outset received FDA clearance for its next-generation Tablo platform, featuring enhanced cybersecurity and connectivity, which is slated for a second-quarter launch. His commercial leadership will be crucial in successfully bringing this new product to market and articulating its value proposition.

For investors, who have seen Outset’s stock decline over the past six months despite a recent 11% weekly gain, this high-profile hire represents a clear commitment to executing a robust commercial strategy. The industry will be watching closely to see if this veteran leader can translate Outset Medical's technological innovation into sustained market dominance and transform the future of kidney care.